Kush Parmar has bought stock on 4 days since Jun 2020

Kush M. Parmar, M.D., Ph.D. is a corporate insider and independent director at Rallybio Corp (RLYB), where he has served on the board since 2018 and through 2024.( As a director of Rallybio, he has helped guide the company’s strategy and financings, including its public listing, drawing on deep experience backing next‑generation life science companies.( In addition to his role at Rallybio, he is a Managing Partner at 5AM Ventures, a leading early‑stage venture capital firm focused on building innovative biotech and life science companies.( He also serves on or has served on the boards of multiple public and private biopharma companies—such as Entrada Therapeutics, Vor Biopharma, Akouos, Arvinas, Homology Medicines and others—and has played key roles in IPOs, acquisitions and major partnerships across this portfolio.(

Parmar trained as an NIH‑sponsored M.D./Ph.D. Physician‑Scientist Fellow in the joint Harvard‑MIT Health Sciences and Technology Program and completed clinical clerkships at Massachusetts General Hospital and Brigham and Women’s Hospital.( He holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a Ph.D. in Experimental Pathology from Harvard University, and an M.D. from Harvard Medical School.( Beyond his investment and board work, he serves on advisory and scientific councils at Princeton University and Harvard Medical School, is a Fellow of the Kauffman Fellows Society, and is active in India’s biotech ecosystem as a co‑founder of Immuneel Therapeutics and a board member of Syngene International.(

Written by Perplexity from public sources.